Skip to main content

AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 12, 2024.

via HealthDay

TUESDAY, Nov. 12, 2024 -- For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial infarction (MI), and recurrent stroke, according to a study presented at the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.

Mohammad Ali Sheffeh, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the efficacy of GLP-1 RA or SGLT-2i initiation for reducing mortality or cardiovascular events among adults with ischemic stroke. Data were included for 7,044 individuals (mean age, 72 ± 14 years).

The researchers found that 6 percent of the participants had a second stroke, 6 percent had an incident MI, and 53 percent died during a median follow-up of three years. In the univariate analysis, those on an SGLT-2i/GLP-1 RA had a reduced risk for mortality, incident MI, and composite. After multivariable adjustment, these associations remained significant and were not affected by minimum time of exposure. In the multivariate analysis, SGLT-2i/GLP-1 RA use was also associated with recurrent ischemic stroke. In most sub-analyses of individual medications, all associations remained significant, except for the association between GLP-1 RA and recurrent stroke.

"The results of the study are consistent with other research about the preventive role of these medications against cardiovascular disease in people with obesity or heart failure," Sheffeh said in a statement.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Risk for Dementia, Ischemic Stroke, Mortality Lower With GLP-1 Receptor Agonists in T2D, Obesity

TUESDAY, July 22, 2025 -- For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke...

Living in Marginalized Neighborhoods Linked to Adverse Outcomes in Acute MI

THURSDAY, July 10, 2025 -- For younger acute myocardial infarction (AMI) survivors, living in marginalized neighborhoods is associated with adverse outcomes, according to a study...

Delirium Common Among Critically Ill Patients With Stroke

TUESDAY, July 8, 2025 -- More than one in four critically ill patients with stroke experience delirium, according to a study published online July 1 in the American Journal...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.